Outcomes and associated factors after melphalan 140 mg/m² autologous hematopoietic cell transplantation for multiple myeloma in patients over 70 years of age
Retrospective analysis shows higher Karnofsky scores improve outcomes in multiple myeloma patients, suggesting the need for comprehensive risk stratification.
Key Points
Evaluate outcomes and predictive factors after melphalan 140 mg/m² autologous hematopoietic cell transplantation in patients over 70 years.
Retrospective multicenter analysis using CIBMTR registry data
Participants aged ≥70 years with multiple myeloma undergoing auto-HCT
Assessment of treatment-related mortality, relapse, disease-free survival, and overall survival using Cox models
Included 1,224 patients with mean age 73.2 years
At 24 months, TRM was 4.6%, relapse 26%, DFS 69.3%, OS 87.8%
Higher Karnofsky score (≥90) associated with better overall survival